The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines by Reichert, T E et al.
The action of interleukin-2 (IL-2) on haematopoietic cells is medi-
ated by its binding to the IL-2R complex, consisting of at least
three distinct chains: a, b and g (Waldmann, 1991; Nakanishi et al,
1992; Taniguchi and Minami, 1993). These three non-covalently
associated chains form a high affinity IL-2R, with Kd of 10–11 M.
The IL-2R-a chain (p55) alone binds the ligand with a low affinity
(Kd = 10–8 M), and the IL-2Rb chain (p70/75) in association with
the g chain (p64) is an intermediate affinity IL-2R with Kd =
10–9 M (Arzt et al, 1992). IL-2-initiated signalling via IL-2R,
necessary for lymphocyte activation and proliferation, is mediated
primarily through the IL-2Rb and g chains, because the a chain
lacks the cytoplasmic domain for signal transduction (Nakanishi et
al, 1992).
Recent studies from our laboratory and others have demon-
strated the expression of IL-2R, primarily IL-2Rb and g chains, as
well as IL-2 in human tumour cells (Saneto et al, 1986; Arzt et al,
1992; Plaisance et al, 1992, 1993; Weidmann et al, 1992; Alileche
et al, 1993; Ciacci et al, 1993; Rimoldi et al, 1993; Yasamura et al,
1994; Lin et al, 1995; McMillan et al, 1995). These components of
the IL-2 pathway were expressed in tumour cells grown in the
absence of exogenous IL-2 as well as in tumour biopsy specimens
(Weidmann et al, 1992; Lin et al, 1995). Our findings, which
suggest that endogenous IL-2 might be involved in the regulation
of tumour cell growth, include: (1) the localization of intracyto-
plasmic IL-2 to the Golgi complex; (2) increased expression of
IL-2 mRNA and protein in mitotic tumour cells; and (3) the asso-
ciation between increased IL-2 expression and a decreased level of
p27Kip1 cyclin-dependent kinase (CDK) inhibitor in mitotic cells
(Reichert et al, 1998a). Previous results from other laboratories
have also suggested that, similar to its role in proliferation of
haematopoietic cells, IL-2 may be a growth hormone for tumour
cells (Alileche et al, 1993).
The detection of IL-2R and of intracytoplasmic IL-2 in human
tumour cells and normal epithelial cells raises the possibility that a
functional IL-2/IL-2R pathway may exist in tumour or tissue cells
of non-haematopoietic origin. Previous observations from our
laboratory indicated that the addition of exogenous IL-2 at high
concentrations (in nM to  mM quantities) or of antibodies (Abs)
recognizing the IL-2 binding site on the IL-2Rb chain expressed in
carcinoma cell lines inhibited their growth (Rabinowich et al,
1992; Yasamura et al, 1994; Lin et al, 1995). In contrast, recent
results showed that endogenous IL-2, produced by tumour cells in
the absence of exogenous IL-2, behaved like a cell cycle-associ-
ated protein and was involved in promoting cell cycle progression
in carcinomas (Reichert et al, 1998a). These data prompted us to
investigate the role of endogenous IL-2 in tumour cell growth.
In this study, we have used immunological as well as molecular
strategies to demonstrate that IL-2 produced by human carcinomas
is not only involved in tumour cell growth but may also protect
tumour cells from apoptosis.
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Summary Interleukin (IL-2) and IL-2Rb/g have been shown to be expressed in human carcinomas in culture and in situ. Recently, expression
of endogenous IL-2 and IL-2R in the cytoplasm was found to be up-regulated in tumour cells undergoing mitosis. This observation suggested
that similar to its role in lymphocytes, the IL-2/IL-R pathway is involved in the regulation of carcinoma cell proliferation. Metabolic labelling
followed by immunoprecipitation and Western blot results showed that IL-2 in carcinomas was identical to that in human lymphocytes.
However, tumour cells did not secrete IL-2 detectable by immunoassays, although membrane-associated IL-2 was detectable on a proportion
of these cells cultured in the absence of exogenous IL-2. Antibodies to IL-2 failed to inhibit proliferation of carcinoma cells, but antibodies
specific for the ligand-binding site of the IL-2R were growth inhibitory. Growth of tumour cells was also inhibited by the immunosuppressive
drugs, cyclosporin A (CsA), FK506 and rapamycin (RPA), known to interfere with the IL-2 pathway in lymphocytes. To further confirm the role
of endogenous IL-2 in the growth of carcinomas, tumour cells were incubated with an IL-2-specific antisense oligonucleotide. The treatment
was shown to transiently inhibit IL-2 mRNA and IL-2 protein expression as well as proliferation of tumour cells. Tumour cells treated with
IL-2-specific antisense oligonucleotide demonstrated increased apoptosis in comparison to untreated or sense oligonucleotide-treated control
cells. The data indicate that in human carcinomas, endogenous IL-2 promotes growth and protects tumour cells from apoptosis. © 1999
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MATERIALS AND METHODS
Cell lines
Human squamous cell carcinoma of the head and neck (SCCHN)
cell lines (PCI-1 and PCI-13) and the HR gastric carcinoma cell
line have been established in our laboratory, as previously
described (Heo et al, 1989; Shimizu et al, 1991). These lines were
maintained in Dulbecco’s modified-minimal essential medium
(DMEM) containing 10% (v/v) heat-inactivated (56°C, 30 min)
fetal calf serum (FCS), 2 mM glutamine, 100 U ml–1 penicillin and
100 mg ml–1 streptomycin (all from Life Technologies, Inc., Grand
Island, NY, USA). The cells were passaged by trypsinization
(0.25% trypsin solution, Life Technologies, Grand Island, NY,
USA) and were routinely tested for mycoplasma (Gen-Probe, San
Diego, CA, USA). For experiments described here, the cell lines
were cultured in the same DMEM but supplemented with 1% (v/v)
of FCS.
Antibodies to human IL-2 and IL-2R chains
Unlabelled polyclonal and monoclonal antibodies (mAbs) to IL-2
were purchased from Genzyme, Cambridge, MA, USA, Becton
Dickinson, Mountain View, CA, USA or R&D Systems,
Minneapolis, MN, USA. Labelled mAbs to IL-2 were obtained
from PharMingen, San Diego, CA, USA or Biosource
International, Camarillo, CA, USA. Unlabelled mAbs to the a
chain (CD25) of IL-2R were purchased from Dako Corporation,
Carpinteria, CA, USA; and fluourescein isothiocyanate (FITC)-
conjugated mAbs to CD25 from Becton Dickinson. The mAbs
TU27 to the b chain of IL-2R was kindly provided by Dr Junji
Hamuro (Ajinomoto Co., Inc., Kawasaki, Japan). The FITC-
conjugated mAb to the b chain (anti-CD122) of IL-2R was
obtained from Endogen (Boston, MA, USA) and unlabelled mAbs
Mik-b2 and Mik-b3 to the b chain of IL-2R were purchased from
PharMingen. Unlabelled antibodies to IL-2Rb chain, which do not
interfere with the ligand binding: 341 and 561, were generously
provided by Dr Paul Sondel (University of Wisconsin, Madison,
WI, USA). The polyclonal chicken Ab to the IL-2R-g chain was
purchased from Promega (Madison, WI, USA).
Labelled or unlabelled isotype control antibodies (IgG, IgM,
IgG2a) were purchased from Becton Dickinson, Dako Corporation,
PharMingen or Biosource International. Isotype control for the
IL2R-g chain was chicken IgG purchased from Pierce, Rockford,
IL, USA.
Immunostaining for IL-2 and IL-2R
Tumour cell monolayers were grown to confluence (70–80%) on
Labtek chamber slides (CMA, Houston, TX, USA). The slides
were rinsed in cold phosphate-buffered saline (PBS) (2 ´ 3 min).
The cells were pre-fixed for 5 min in 2% (w/v) paraformaldehyde
(PFA) and then permeabilized with 0.1% Triton X-100 in PBS for
10 min before staining with mAbs. Indirect immunoperoxidase
(IP) method (Chen et al, 1987) was used for staining with anti-IL-
2 Abs (30 mg ml–1). Prior to staining, polyclonal anti-IL-2 Ab was
preincubated with excess rIL-2 (Chiron Corp., Emeryville, CA,
USA) to verify its specificity. Aliquots (300 ml) of the Ab were
mixed with equal volumes of rhIL-2 (1.5 ´ 106 Cetus units ml–1)
and incubated at room temperature for 1 h. This preincubation
completely eliminated cytokine-specific staining. Isotype control
Abs (IgG mouse, IgG chicken and IgG rabbit) were used as
appropriate. Slides were examined in an Olympus BH-2 light
microscope to determine expression of IL-2 and IL-2R proteins in
tumour cells.
Flow cytometry
Expression of IL-2 and the different IL-2R chains on various
tumour cell lines was determined by flow cytometry, using PE- or
FITC-conjugated anti-IL-2, anti-CD25, anti-CD122 or unlabelled
TU27 or anti-common g chain Abs. For surface staining, tumour
cell suspensions were adjusted to the concentration of 1 ´ 106 cells
ml–1 in 0.1% (v/v) sodium azide in PBS and incubated with pre-
determined dilutions of appropriate Abs for 30 min at 4°C, washed
and fixed with 1% (v/v) PFA-PBS. All Abs were pre-titred on
normal non-activated or IL-2 activated PBMC to select optimal
dilutions. To detect intracellular protein expression, tumour cells
were first pre-fixed with 2% (w/v) PFA in PBS for 20 min at 4°C,
washed twice, permeabilized with 0.1% saponin (Sander et al,
1991) and stained with appropriate Abs. For indirect staining, cells
were incubated first with the primary Ab, washed three times and
then incubated with the FITC-conjugated second Ab (goat anti-
mouse or goat anti-chicken). The appropriate isotype IgG, chicken
IgG or PBS alone were used as controls in all experiments.
Transduction of tumour cells with the IL-2 gene
PCI-1 or HR tumour cell lines were stably transduced with the
retroviral vector DFG-hIL-2-Neo, using supernatants of the pack-
aging cell line, CRIP, selected in G418 medium and examined for
the ability to secrete IL-2 using an enzyme-linked immunosorbent
assay (ELISA), as previously described (Nagashima et al, 1997a,
1997b). As control, carcinoma cell lines were also transduced with
the LacZ gene.
ELISA for IL-2
Tumour cells were cultured, as described above, harvested,
washed in PBS and subjected to a series of three freeze and thaw
cycles to disrupt the tumour cells. Cytosol was diluted 1/4 with
PBS and tested for the presence of IL-2 by ELISA (Endogen,
Cambridge, MA, USA). The kit was calibrated against the WHO
International Cytokine Standard. Interassay variability was moni-
tored by the use of IL-2-rich supernatants which were prepared in
bulk by activation of normal human peripheral blood mononuclear
cells (PBMCs) with PHA-P and stored in small aliquots at –80°C.
These supernatants were used as a positive control in every assay.
The CV for IL-2 ELISA, established on the basis of 50 determina-
tions, was 15 ± 3%.
MTT proliferation assay
Cell lines were cultured in medium containing 1% (v/v) heat-
inactivated (56°C, 30 min) FCS or in the presence of various
concentrations of Abs, including TU27, Mikb2, mAb 341, poly-
clonal rabbit anti-human IL-2 or mouse anti-human IL-2 mAb.
Growth of these cells was measured using a colourimetric MTT
[3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide]
assay, as described by us previously (Lin et al, 1995). The OD
readings at the wavelength of 540 nm were obtained from at least
four wells per each concentration of every Ab used to modulate824 TE Reichert et al
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growth and the mean OD540 ± s.d. calculated. Inhibition of prolifer-
ation in the presence of the Ab was calculated as the percentage of
control cell growth, using the formula:
[3H]-thymidine incorporation assay
To determine effects of cyclosporin A (CsA), FK 506 or
rapamycin (RPA) on tumour cell growth, incorporation of [3H]-
thymidine into cellular DNA of HR, PCI-1 or PCI-13 cells in the
presence of different concentrations of these drugs was measured.
CsA was obtained from Sandoz (Basel, Switzerland), FK506 from
Fujisawa Pharmaceuticals (Osaka, Japan) and RPA from Ayerst
(Wyath Research, Princeton, NJ, USA). Tumour cell monolayers
in 96-well, flat-bottomed plates (5 ´ 103 well–1) were incubated in
tissue culture medium (control) or different dilutions of CsA, FK
506 or RPA in the absence if IL-2 for 24, 48 or 72 h at 37°C and
5% carbon dioxide in air. The cultures were pulsed with 1 mCi
well–1 of [3H]-thymidine (specific activity: 1 Ci mM–1; NEN,
Boston, MA, USA) 6 h prior to harvest. Cells were washed three
times, trypsinized, subjected to two freeze and thaw cycles, and
harvested with a Skatron harvester (Tranby, Norway).
Radioactivity was determined in a b counter. Results were calcu-
lated as the mean cpm of four replicate determinations and were
expressed as per cent of control counts.
Metabolic labelling and immunoprecipitation studies
Jurkat cells used as a positive control for these studies were
activated by incubation in the presence of phytohaemagglutinin
(PHA) at 1 mg ml–1 and phorbol myristic acetate (PMA) at
50 ng ml–1 for 24 h. For metabolic labelling, Jurkat cells or tumour
cells were harvested, washed and placed in the methionine-free
medium containing [35S]-methionine (Amersham; sp. act >
1000 Ci mmol–1) for 8 h. The cells were then lysed in the buffer
containing 1% Triton X-100, 1 mM iodoacetamide, 0.2 U ml–1
aprotinin and 1 mM phenylmethylsulphonyl fluoride (PMSF)
prepared in TSA solution (0.01 M Tris–HCl, 0.14 M sodium chlo-
ride, 0.025% sodium azide). The lysates were precleared with
Protein A-Sepharose (Sigma) and reacted overnight with poly-
clonal rabbit anti-IL-2 Ab (Genzyme) at the concentration of 1 mg
Ab per 200 ml lysate. Samples were incubated for 2 h at 4°C with
Protein-A Sepharose prior to centrifugation at 200 g for 2 min.
Pellets were washed twice with 0.1% Triton X-100 prepared in
TSA solution, then with TSA and, finally, with 0.05 M Tris–HCl
pH 6.8. After washing, pellets were boiled for 5 min in sodium
dodecyl sulphate (SDS)-sample buffer with 5% 2-mercaptoethanol
and subjected to 15% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE). Gels were dried and exposed to film at –70°C for
24–96 h. To confirm specificity, 1 mg of anti-IL-2 Ab was
absorbed with 20 mg of IL-2 (ratio of 20:1; Chiron) for 4 h at 4°C
prior to its use for immunoprecipitation.
Western blots
Cell lysates prepared from 1 ´ 106 carcinoma cells, Jurkat cells or
YT, an NK-cell line, were electrophoresed on a gradient SDS poly-
acrylamide gel (4–20%) and then electrophoretically transferred to
a nitrocellulose membrane. The nitrocellulose blot was blocked,
washed and incubated with goat anti-human IL-2 Ab purchased
from R&D Systems at a final concentration of 0.1 mg ml–1. This
process was repeated twice. The second antibody was labelled
with horseradish peroxidase, and an enhanced chemiluminescence
(ECL) system was used for detection.
mRNA analysis by RT-PCR
Total RNA was extracted from tumour cells transduced with the
IL-2 gene or with the lacZ gene as control, using a single step
method with the RNAzol solution (Chomczynski and Sacci, 1987).
RNA (100 ng) was recovered from each sample, transcribed and
amplified by PCR as previously described (Nagashima et al,
1997a, 1997b).
The primers for IL-2 were as follows: sense: 5¢-GTCA-
CAAACAGTGCACCTAC-3¢; antisense: 5¢-CCCTGGGTCT-
TAAGTGAAAG-3¢; and the primers for b actin were: sense:
5¢-GGGTCAGAAGGATTCCTATG-3¢, antisense: 5¢-GGTCT-
CAAACATGATCTGGG-3¢. For PCR, 35 cycles of amplifications
were used with denaturing at 94°C for 1 min, annealing at 62°C for
1 min, and extension at 72°C for 1 min. The PCR was performed
under conditions described previously (Nagashima et al, 1997a).
Antisense oligonucleotide treatment
Based on the data indicating that IL-2 expressed in tumour cells
was identical to that in lymphocytes, nucleotide sequences were
selected in the 5¢ coding region of hIL-2. The antisense and sense
sequences were: 5¢-CAGGAGTTGCATCCTGTACAT-3¢ (ASO);
5¢-ATGTACAGGATGCAACTCCTG-3¢ (SO).
These nucleotides were phosphorothioated and purified by
column chromatography in the DNA synthesis facility at the
University of Pittsburgh. To study their uptake by tumour cells, the
oligonucleotides were fluorescein-labelled, using the fluoro-
Amp™ T4 kinase Green Oligonucleotide Labeling System
(Promega), purified, adjusted to an appropriate DNA concentra-
tion and mixed with a cationic lipid transfection reagent N-[1-(2,3-
dioleoyloxy)-propyl]-N,N,N-trimethyl ammonium methylsulphate
(DOTAP, Boehringer Mannheim, Indianapolis, IN, USA). This
reagent has been shown to enhance DNA uptake by cells and also
to protect oligonucleotides from nucleolytic degradation within
the cell (Degolos et al, 1991). Tumour cells were maintained in
reduced serum (0.5–1%) medium to limit the degradation of
oligonucleotides by serum-derived nucleases (Cappacioli et al,
1993). In preliminary experiments, cells were treated with DOTAP
and labelled oligonucleotides at final concentrations of 5 ml
DOTAP per 1 mg oligonucleotide for 24 h, washed free of the
oligonucleotide in DOTAP-containing medium and examined in a
fluorescent microscope for intracytoplasmic staining. In growth
inhibition experiments, cells were plated at the concentration of
5 ´ 103 cells well–1 in wells of a 96-well plate. On the following
day, the cells were treated with various concentrations of oligo-
nucleotides, ranging from 0.3 to 10 mM, complexed with DOTAP.
Following, 24, 48 or 72 h incubation, growth of tumour cells was
measured in an MTT assay, as described above.
Apoptosis assay
Tumour cells, either PCI-1 or PCI-13, were cultured in the
presence of medium containing IL-2 sense oligonucleotide (SO) or
IL-2 antisense oligonucleotide (ASO) at a final concentration of
experimental OD
1–  ´ 100,
control OD
where control = OD of tumour cells cultured in medium alone.Endogenous IL-2 in tumour cell growth 825
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1 mM, as described above, for 8, 24 or 48 h. Cells were harvested
by trypsinization, washed and tested for: (a) the presence of
endogenous IL-2 by flow cytometery; and (b) evidence of apop-
tosis, as assessed in TUNEL assays. The TUNEL assay was
performed using reagents purchased from Boehringer Mannheim,
as previously described by us (Whiteside et al, 1998).
Statistical analysis
The results were analysed using the Mann–Whitney U-test. The
differences were considered significant when P values were
< 0.05.
RESULTS
IL-2 expression in human carcinomas
The presence of IL-2 mRNA and protein in tumour cells in vitro
and in situ has been previously demonstrated in our laboratory
(Lin et al, 1995; Reichert et al, 1998a, 1998b). Also, endogenous
IL-2 was detectable in the tumour cell cytosol by immunoassays at
relatively low levels of 40–60 pg ml–1 per 5 ´ 106 cells disrupted
by rapid freezing and thawing (Lin et al, 1995). To confirm the
presence of IL-2 in carcinoma cells, tumour lysates were prepared
and Western blots performed, using anti-human IL-2 Ab and
human recombinant IL-2 (Chiron) as a positive control (Figure
1A). This Western blot analysis showed that the 14.4-kDa band
detected in tumour lysates by anti-IL-2 Ab corresponded to that
obtained with rIL-2. Next, metabolic labelling with [35S]-methio-
nine followed by immunoprecipitation was performed, using PCI-
1 cells and activated Jurkat cells as a positive control. As indicated
in Figure 1B, the bands corresponding to IL-2 on the gel were
identical for tumour-derived and lymphoid cell-derived IL-2.
Furthermore, absorption with anti-IL-2 Abs eliminated the IL-2
band (Figure 1B), confirming that it corresponded to immuno-
precipitated IL-2. In addition, immunoprecipitation experiments
utilizing goat anti-human IL-2 Abs or isotype IgG control and
performed with lymphoid or tumour cell lysates confirmed expres-
sion of the 14.4-kDa IL-2 band (data not shown). These experi-
ments demonstrated that endogenous IL-2 in tumour cells was
identical to that expressed in and produced by normal lymphoid
cells.
Metabolic labelling of tumour cells allowed for the detection of
IL-2 in concentrated (20´) supernatants of these cells (data not
shown). The finding indicated that very small quantities of IL-2
were released by tumour cells. However, in numerous experi-
ments, we have failed to detect IL-2 in unconcentrated super-
natants of the same tumour cells by ELISA, in spite of abundant
expression of IL-2 in the Golgi zone of these cells, as illustrated in
Figure 2A. IL-2 expression in tumour cells was similar to that
usually seen for IL-2 in activated Jurkat cells (Figure 2E). In
biological assays, using an IL-2-dependent CTLL cell line,
minimal levels of IL-2 were detectable in tumour cell supernatants
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Figure 1 Expression of IL-2 in human tumour cells. (A) Western blots of
tumour cell lysates obtained from various tumour cells and of human rIL-2
(5 ng) used as control. Anti-human IL-2 Ab was used to visualize the
14.4 kDa band. Activated Jurkat and YT, an NK cell line, are used as positive
controls and non-activated Jurkat as a negative control. PCI-13 IL-2 and HR-
IL2 are tumour cells stably transduced with the hIL-2 gene. HR and PCI-4b
are non-transduced carcinoma cell lines. (B) Metabolic labelling and
immunoprecipitation of IL-2 in Jurkat cells (control) and PCI-1 tumour cells.
Autoradiography following separation of cell lysates on PAGE was performed
using samples precipitated in the presence of normal rabbit serum as control
(lanes 1 and 4); of rabbit Ab to hIL-2 (lanes 2 and 5); or of rabbit Ab to hIL-2
absorbed with an excess of rIL-2 (lanes 3 and 6). The arrow heads show the
position of the IL-2 band (14 400 kDA) in lanes 2 and 5. The difference in
intensity of non-specific bands in lanes 5 and 6 is likely due to the use of
unabsorbed versus absorbed Abs to hIL-2. Results of one experiment of
three performed are shown
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Figure 2 Immunostaining of tumour cells for expression of IL-2 or IL-2R.
(A) PCI-1 cells in a monolayer are immunostained for endogenous IL-2; Mag
´ 1000. (B and C) PCI-1 stained with anti-IL-2Rg chain Ab or with TU27 Ab
for IL-2Rb Ab respectively; Mag ´ 1000. (D) PCI-1 cells are stained with
isotype control Abs (negative control); Mag ´ 250. (E) Activated Jurkat T-cells
are stained with anti-IL-2 Ab (positive control); Mag ´ 4000
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(Nagashima et al, 1997a, 1997b). Moreover, co-incubation of
carcinoma monolayers with CTLL cells always induced a low
level of CTLL growth, as evidenced by increased [3H]-thymidine
incorporation (Nagashima et al, 1997a,b). Also, IL-2 expression
on the surface of tumour cells was detectable by flow cytometry
(Lin et al, 1995). In addition to IL-2, immunoperoxidase staining
has shown the presence of abundant IL-2Rb and g in the cytoplasm
of carcinoma cells (Figure 2 B, C). Taken together, these data indi-
cate that although the components of the IL-2 pathway are present
in carcinoma cells, endogenous IL-2 is not actively secreted but
rather utilized by these cells.
Effects of Abs to IL-2 or IL-2R on growth of tumour
cells
To begin to study the role of the IL-2 pathway in tumour cells, we
examined effects of various Abs to IL-2 or the IL-2R chain on
growth of tumour cell lines. As shown in Figure 3, Abs to IL-2 did
not inhibit growth of parental HR, PCI-1 or PCI-13 cells, which do
not secrete IL-2. In these experiments, tumour cell monolayers
were incubated in the presence of different concentrations of the
anti-IL-2 Abs for 3 days, and their growth was assessed in MTT or
[3H]-thymidine incorporation assays. These experiments, repeated
at least three times with all three tumour cell lines were consis-
tently negative and indicated that growth of tumour cells, which
did not secrete measurable levels of IL-2, could not be inhibited by
Abs to IL-2.
In a separate series of experiments, we showed that Abs to
the binding site for IL-2 on the IL-2Rb chain, such as TU27 or
Mik-b2, used at the concentration > 0.05 mg ml–1 significantly
inhibited (P < 0.01) tumour cell growth (Figure 4). Isotype control
Abs used in all blocking experiments did not inhibit tumour cell
growth. Abs to epitopes on IL-2Rb chain not involved in ligand
binding (e.g. Mik b3 or Ab 341) were not growth inhibitory (data
not shown).
Not only Abs to the IL-2 binding site, but also exogenous rIL-2
used at concentrations > 0.005 nM was found to inhibit growth of
tumour cell lines (Figure 5). These results taken together with our
previously reported data of in vivo growth inhibition by rIL-2
(Rabinowich et al, 1992; Weidmann et al, 1992; Yasamura et al,
1994), indicate that both the Abs to the IL-2 binding site on the
Table 1 Effects of CsA, FK506 and RPA on growth of tumour cellsa
HR PCI-1 PCI-13
Treatment % Growth control
CsA-24 h 58 ± 5* 60 ± 7* 63 ± 4*
(1 mg ml–1)
CsA – 72 h 75 ± 3* 40 ± 8* 80 ± 5*
(1 mg ml–1)
FK – 24 h 65 ± 5* 63 ± 4* 65 ± 4*
(0.5 mg ml–1)
FK – 72 h 70 ± 4* 80 ± 3* 75 ± 4*
(0.5 mg ml–1)
RPA – 24 h 83 ± 4* 86 ± 6 85 ± 4
(10 mg ml–1)
RPA – 72 h 40 ± 5* 60 ± 2* 51 ± 6*
(10 ng ml–1)
aProliferation of HR, PCI-1 and PCI-13 cells incubated in the presence or
absence of the immunosuppressive drugs was measured following 24 h
(short-term) or 72 h (long-term) incubation. Growth of tumour cells was
measured in [3H]-thymidine incorporation assays. The doses of the drugs
were selected to give about 40–50% growth inhibition relative to medium
controls. The data are mean values ± s.d. of four replicates. A representative
experiment of 3 performed is shown. The asterisks indicate significant
inhibition of proliferation (P < 0.05) compared to control cells incubated with
medium alone.
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Figure 3 Proliferation of HR, PCI-1 and PCI-13 cells incubated for 3 days in
the presence of Abs to IL-2 at the concentration of 1 mg ml–1. Proliferation
was not inhibited at this or other Ab concentrations tested (0.01–10 mg ml–1).
Proliferation was measured in 3-day MTT assays. The data are presented as
the % of cell growth in medium and are means ± s.d. of three replicate wells
in a representative experiment of four performed. Isotype control IgG was
used as control
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Figure 4 Inhibition of growth of tumour cells in the presence of anti-IL-2Rb
mAbs Mikb2, TU27 or control IgG. On day 3, growth of tumour cells was
measured in MTT assays as described in Materials and Methods. The data
are mean values ± s.d. of four replicates in a representative experiment of at
least 3 performed. The asterisks indicate significant inhibition in proliferation
(P < 0.05) compared to control cells incubated with isotype control IgG
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Figure 5 Inhibition of tumour cell (PCI-13) proliferation by exogenous
recombinant (r)IL-2. Tumour cells were incubated with various concentrations
of human rIL-2, and their growth was measured in [3H]-TdR incorporation
assays. The data are presented as mean ± s.d. percentages of their growth
relative to medium alone. Significant inhibition of growth (P < 0.05) is
indicated by asterisks. A representative experiment of 5 performed is shownEndogenous IL-2 in tumour cell growth 827
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IL-2Rb chain and exogenous IL-2 at high molar concentrations
can induce a growth-inhibitory signal in tumour cells, possibly
through cross-linking of the IL-2R.
In contrast to the effects of exogenous IL-2 on tumour cell
growth reported above, IL-2 made by tumour cells appeared to
enhance their cell cycle progression (Reichert et al, 1998a). The
presence in the cytoplasm of these tumour cells of both IL-2 and
IL-2R was demonstrated in immunostaining (data for IL-2R are
not shown), suggesting that the intracrine IL-2 pathway was oper-
ative in tumour cells. Furthermore, this pathway seemed to have
opposite biological effects from that driven by exogenous IL-2.
Effects of cyclosporin A, FK 506 or rapamycin on
growth of tumour cell lines
In view of the preliminary evidence indicating that the IL-2/IL-2R
complex may play a role in tumour cell growth, we next attempted
to interfere with the IL-2 pathway in tumour cells and observe
effects on growth. CsA and FK506 are known to inhibit activation
of the IL-2 gene transcription in T-cells (Schreiber, 1991).
Rapamycin, despite its structural similarity to FK506, has
no effect on IL-2 production, but it potently inhibits
autocrine/paracrine responses of T-cells to IL-2 and, thus, the
progression from G1 to S phase in activated T lymphocytes
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(Schreiber, 1991; Terada et al, 1993). In preliminary studies we
observed that tumour cells incubated in the presence of CsA or
FK506 down-regulated expression of intracytoplasmic IL-2. We,
therefore incubated tumour cells with different concentrations of
these drugs in order to examine their effects on tumour cell
growth. As shown in Figure 6, FK506 was growth inhibitory to
tumour cells in culture. Similar results were obtained with CsA
and RPA (data not shown). To minimize possible toxic drug-
induced effects on these cells, the dose of each drug inducing close
to 50% of growth inhibition was selected for further studies. At
these selected drug doses, we examined the short-term effects
(24 h) as well as the long-term effects (72 h) of the drugs on
growth of tumour cells. As shown in Table 1, CsA at the doses of
1 mg ml–1 and FK506 at the dose of 0.5 g ml–1 inhibited growth (up
to 45%) of the tumour cell lines after 24 h (P < 0.05) as well as
72 h (P < 0.05) of incubation. The growth-inhibitory effect of
these drugs was often greater after 24 h than after 72 h incubation.
Rapamycin at the dose of 10 ng ml–1 had very little effect on
tumour cell growth after 24 h (not significant), but it induced a
significant (P < 0.05) reduction in growth after 72 h (Table 1).
These results were not merely a manifestation of drug toxicity on
tumour cells, because in the presence of 200 pM IL-2, drug-
induced growth inhibition was significantly reversed (data not
shown). Overall, the data suggest that drugs which interfere with
the IL-2 pathway in tumour cells also inhibit their growth in
culture.
Effects of IL-2-specific antisense oligonucleotides on
IL-2 expression and tumour cell growth
To specifically interfere with the IL-2 pathway in tumour cells, we
designed antisense oligonucleotides (as well as sense oligonucleo-
tides to be used as controls), which could bind to IL-2 mRNA and
specifically inhibit its translation. A computer program, Oligo
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Primer Analysis Software (National Biosciences, Inc., Plymouth,
MN, USA), was used to narrow the oligonucleotide selection to
those in the 5¢ coding region of IL-2. To optimize conditions for
treatment of the carcinoma cell lines, the selected oligonucleotides
were phosphorothiolated, purified by column chromatography and
labelled with fluorescein for preliminary experiments. Next, a
DOTAP preparation was selected, which was most likely to facili-
tate entry of oligonucleotides into tumour cells. Using fluorescein-
labelled oligonucleotides, we showed that they accumulated in the
cytoplasm of tumour cells after 24 h incubation (Figure 7 A–C). In
contrast, only minimal internalization of the oligonucleotides
occurred in the absence of DOTAP (Figure 7A). The DOTAP was
tested at various concentrations to determine that which was not
toxic to tumour cells following cellular uptake (data not shown).
Finally, using unlabelled antisense (ASO) and sense (SO) oligo-
nucleotides at the concentration range of 0.3–10 mM, we demon-
strated that cultured tumour cells incubated in the presence of
the IL-2-specific ASO, but not SO, for 48 h were significantly
inhibited in growth (P < 0.0001; Figure 8A). Flow cytometry
demonstrated that expression of intracytoplasmic IL-2 protein was
nearly completely abolished following ASO treatment (Figure
8B). Expression of mRNA for IL-2 was significantly decreased at
24 h after treatment with the IL-2 ASO in PCI-1 cells (Figure 8C).
These experiments demonstrated that endogenous IL-2 in tumour
cells plays a role in tumour cell proliferation.
Effects of IL-2 specific antisense oligonucleotides on
tumour cell apoptosis
The inhibition of tumour cell growth in the absence of endogenous
IL-2 expression could be due to an increase in the rate of cell
death. We performed a series of experiments to determine the
effects of IL-2-specific ASO on tumour cell apoptosis. As
compared to untreated controls and to cells treated with the
corresponding SO, tumour cells incubated with the IL-2-specific
ASO were significantly (P < 0.001) more susceptible to DNA
fragmentation in the absence of endogenous IL-2 (Figure 9). The
effects of ASO on tumour cell apoptosis were optimal in 8-h
cultures with PCI-13 and in 24- to 48-h cultures with PCI-1
(Figure 9). These results suggest that endogenous IL-2 modulates
tumour cell growth by protecting them from apoptosis.
DISCUSSION
The presence of IL-2R on the surface of carcinomas and their
ability to synthesize IL-2 suggest that the IL-2/IL-2R pathway is
active in human tumour cells and is involved in tumour cell
growth. Another indication for the existence of an active IL-2
pathway in human carcinomas is the observed inhibition of tumour
cell growth by Abs to the IL-2 binding site on the IL-2Rb chain
expressed on these cells. The two such Abs we used, TU27 and
Mik-b2, significantly decreased tumour cell proliferation, when
used at sufficiently high concentrations. In previously reported
experiments, these Abs were shown to compete with radioactively
labelled exogenous IL-2 for binding to the IL-2R (Weidmann et al,
1992). Both exogenous IL-2 at high (nM or mM) concentrations and
TU27 or Mikb2 Abs induced an inhibitory growth signal upon
binding to IL-2R on carcinoma cells. In contrast, anti-IL-2R Abs,
which recognize the b chain but do not interfere with IL-2 binding,
had no effect on tumour cell proliferation. Thus, cross-linking of
the IL-2Rb binding sites for IL-2 on tumour cells by the exo-
genous ligand available at high concentrations or by Abs to its
binding site leads to negative signalling for growth. The mecha-
nism utilized by this growth inhibitory signal is not clear, but we
have reported earlier that the absence or low expression of the
common JAK3 in HR as well as JAK3 B or M variants associated
with the g chain in SCCHN cells could contribute to altered
downstream signalling mediated via the IL-2Rbg in tumour cells
(Suminami et al, 1998). While cross-linking of IL-2R induces a
negative growth signal, endogenous IL-2 utilized by the tumour
cell in picomolar concentrations via the intracrine or juxtacrine
pathway seems to be necessary for proliferation of these cells.
Several different neutralizing monoclonal Abs or a polyclonal
Ab against IL-2 that we evaluated had no effect on tumour cell
growth. These observations can be explained by the inability of
anti-IL-2 Abs to neutralize endogenous IL-2, which may only be
released by tumour cells in minute quantities and may be largely
bound to IL-2Rb on their surface, as indicated by the flow
cytometry data (Lin et al, 1995). It is also possible that endoge-
nous IL-2 combines with IL-2R in the cytoplasm, as both the
ligand and receptor are detectable in tumour cells by immuno-
staining. Antibody blocking studies, in which the same carcinoma
cells transduced with the IL-2 gene and secreting IL-2 were used,
confirmed that the anti-IL-2 Abs were able to neutralize secreted
IL-2 and inhibit, in part, growth of the transfectants (data not
shown).
The observed lack of growth inhibition by Abs to IL-2 in
tumour cells could be also explained by the ability of carcinomas
to produce other growth factors which could occupy the inter-
mediate affinity IL-2R on tumour cells, preventing binding of anti-
IL-2 Abs. For example, IL-15 has a tertiary structure similar to
that of IL-2 and is known to be able to bind to the b and g chains of
IL-2R and mediate growth-factor activities similar to those of IL-2
(Grabstein et al, 1994; Giri et al, 1995). IL-15 might block access
of IL-2 to IL-2R thus preventing receptor triggering. Surprisingly,
exogenous IL-15 does not induce a growth signal in these carci-
noma cells, possibly because downstream components of the
IL-2Rbg pathway are altered relative to those in T-cells (Suminami
et al, 1998). By immunostaining, we have confirmed expression
of IL-15 protein in our tumour cell lines (data not shown). It is,
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therefore, possible to speculate that this cytokine displaces IL-2
from its receptor on the tumour cell surface and thus effectively
blocks binding of anti-IL-2 Ab to the IL-2/IL-2Rb complex
responsible for signalling. The fluorescence resonance energy
transfer (FRET) data reported by Damjanovich and colleagues
(1997) strengthen this hypothesis by demonstrating that an altered
conformation of the high-affinity IL-2R complex on the cell
surface occurs in the presence of IL-15, allowing the IL-15R a
chain to complex with IL2R b and g subunits (Damjanovich et al,
1997).
To further elucidate the biologic significance of the IL-2/IL-2R
pathway in carcinomas, we incubated these cells with the well
known immunosuppressive agents: cyclosporin A (CsA), FK506
and rapamycin (RPA). CsA and FK506, binding to immunophilins,
inhibit transcription of the IL-2 gene and, therefore, production of
IL-2 in activated T-cells (Schreiber, 1991). The drugs do not
inhibit expression of IL-2R (Kalman and Klimpel, 1983).
Incubation of human carcinomas with CsA and FK506 signifi-
cantly inhibited tumour cell growth in a dose-dependent manner
after 24 h, confirming that the immunophilin-calcineurin-
dependent IL-2 gene activation pathway, known to be active in
T lymphocytes, also operates in tumour cells. The addition of IL-2
to cultures containing these drugs, significantly diminished drug-
induced growth inhibition (data not shown). Rapamycin prevents
the IL-2-mediated elimination of the p27Kipl cyclin-dependent
kinase inhibitor protein and, consequently, the progression from
G1 to S phase in activated T lymphocytes (Nourse et al, 1994). In
our study, RPA had very little effect on tumour cell growth after
24 h but showed a pronounced growth inhibitory effect after 72 h
of incubation. These results indicate that, similar to its effect on
PHA-stimulated T-cells (Terada et al, 1993), RPA interferes with
the IL-2 pathway in cycling, but not resting tumour cells.
Furthermore, inhibition of cell proliferation by RPA could not be
reversed by the addition of exogenous IL-2 at various concentra-
tions (data not shown), again in parallel to results obtained with
PHA-stimulated T lymphocytes (Terada et al, 1993).
Taken together, our initial results suggested that the endogenous
IL-2 pathway in human carcinomas might play an important role
in tumour cell proliferation and survival. Furthermore, immuno-
precipitation/Western blot experiments showed that IL-2 produced
by tumour cells had the same characteristics as IL-2 produced by
lymphoid cells. With the identity of tumour-derived and lympho-
cyte-derived IL-2 confirmed, it became possible to perform a
series of in vitro studies with IL-2-specific ASO, attempting to
disrupt this endogenous pathway. Specifically, ASO and SO
designed to bind to mRNA for IL-2 were generated and delivered
to the cytoplasm of tumour cells by lipofectin, using a cationic
lipid transfection reagent, DOTAP. It was possible to demonstrate
that IL-2-specific ASO treatment temporarily prevented expres-
sion of IL-2 protein and IL-2 message in tumour cells, and that
it also significantly inhibited growth of these cells. The sense
construct, used as control, had no effect on tumour cell growth. In
addition, treatment of tumour cells with ASO, but not SO, signifi-
cantly increased susceptibility of tumour cells to apoptosis. The
antisense strategy allowed us to conclude that in human carci-
nomas, endogenous IL-2 is involved in tumour cell proliferation
and also in protection of tumour cells from apoptosis. Together
with our other data, demonstrating an association between over-
expression of IL-2 protein and decreased expression of p27Kipl, a
cyclin D inhibitor, during the S phase of the tumour cell cycle
(Reichert et al, 1998a), the present results provide compelling
evidence that in tumour cells, similar to lymphoid cells,
endogenous IL-2 is involved in the regulation of cellular division,
proliferation and survival.
The evidence for the presence of the endogenous IL-2 pathway
in human carcinomas and its involvement in tumour cell survival
has important biological implications. Since tumours appear to
express endogenous IL-2 in vivo, as our in situ data indicate
(Reichert et al, 1998b), they are likely to have an active IL-2
pathway. The participation of this pathway in protection of tumour
cells from apoptosis may be important in their survival. A possi-
bility thus presents itself for modulating this pathway by various
strategies, e.g. by exogenous IL-2, capable of delivering a negative
growth signal at high ligand/receptor ratios; immunosuppressive
agents such as CsA, FK506 or RPA, or even IL-2-specific ASO
(Stein and Cheng, 1993), in an attempt to control tumour cell
growth.
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